B-Cell Lymphoma - Pipeline Insight, 2024

This “B-Cell Lymphoma - Pipeline Insight, 2024,” report provides comprehensive insights about 160+ companies and 170+ pipeline drugs in B-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

B-Cell Lymphoma Understanding

B-Cell Lymphoma: Overview

B-cell lymphoma is a type of non-Hodgkin lymphoma that originates in the B-cells. It is the most common type of lymphoma and about 85% of all lymphomas in the United States are B-cell. Common symptoms associated with lymphoma include painless enlargement of one or more lymph node areas, fever, night sweats, and weight loss. Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell lymphoma. DLBCL typically affects older people and accounts for one out of three cases of non-Hodgkin lymphoma. This type of B-cell lymphoma usually begins as a mass in a lymph node, but can also form in particular sites such as bone, intestine, the spinal cord or brain. Standard treatment for DLBCL generally involves months of conventional chemotherapy, and overall cure rates in the last 15 years have been about 70%. Diffuse large B-cell lymphoma has long been treated as a single disease, but it is now categorized into many different subtypes based on their molecular features. There are two large subtypes: germinal center b-cell (GCB) and activated b-cell (ABC). B-cell lymphomas arise from different stages of differentiation of B-cells and constitute a broad spectrum, extending from small- to large-cell types, and from low to high grades of clinical behavior. It has undergone several terminologies and classifications. Because of the diverse terminology that is used in the multiple classifications of lymphomas, there have been attempts to develop uniform pathologic descriptions with clinical usefulness. The current WHO classification uses morphologic, immunophenotypic, genotypic, and clinical features to classify the lymphoid neoplasms into five broad categories as precursor B-cell neoplasms, peripheral B-cell neoplasms, precursor T-cell neoplasms, peripheral T-cell neoplasms and Hodgkin lymphoma. Hodgkin lymphoma though originates from B-cell has distinctive pathologic features and is treated as a separate entity. The clinical presentation of the various lymphoid neoplasms is most often determined by the anatomic distribution of disease. Two-thirds of non-Hodgkin’s Lymphomas present as enlarged nontender lymph nodes. The remaining one-third of NHLs present with symptoms related to the involvement of extranodal sites leading to mass effect, obstructive and compressive signs and symptoms. Treatment includes chemotherapy, steroids, radiation therapy and marrow transplantation. About 95% of children obtain a complete remission, and 75-85% are cured with chemotherapy, whereas only 35-40% of adults are cured. Treatment of t(9;22)-positive ALLs with BCR-ABL kinase inhibitors in combination with conventional chemotherapy is highly effective and has greatly improved the outcome in children.

B-Cell Lymphoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the B-Cell Lymphoma pipeline landscape is provided which includes the disease overview and B-Cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth B-Cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, B-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence B-Cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve B-Cell Lymphoma.

B-Cell Lymphoma Emerging Drugs Chapters

This segment of the B-Cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

B-Cell Lymphoma Emerging Drugs

Odronextamab: ZAI Lab Odronextamab is a human IgG4-based bispecific antibody that binds to CD3, a T-cell antigen associated with the T-cell receptor complex, and CD20, a B-cell surface antigen present on normal B cells and several B cell lineage malignancies. Odronextamab is currently being studied in a potentially pivotal Phase 2 study in B-cell non-Hodgkin lymphoma (B-NHL), including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL). In April 2020, Zai Lab obtained exclusive rights to develop and commercialize odronextamab in greater China from RegeneronPharmaceuticals.

NKTR-255: Nektar Therapeutics NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body's innate and adaptive immunity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular cytotoxicity molecules as well as to enhance CAR-T therapies. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Relapsed/Refractory Large B-cell Lymphoma.

Zilovertamab Vedotin: Merck Sharp & Dohme LLCZilovertamab vedotin is under development for the treatment of solid tumors, blood cancer including advanced or metastatic urothelial carcinoma of renal pelvis, ureter (upper urinary tract), bladder, or urethra, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, triple-negative breast cancer (TNBC), diffuse large B-cell lymphoma, or Richter transformation lymphoma. It is administered through intravenous route of administration. It acts by targeting ROR1 antigens expressing cells. The drug candidate is linked to UC-961-linker-monomethyl auristatin E (MMAE) ADC that preserves the high-affinity binding and specificity of UC-961 and allows for ROR1-targeted intracellular release of MMAE. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Abexinostat: Xynomic Pharmaceuticals Abexinostat (PCI-24781) is under development for the treatment of metastatic renal cell carcinoma, follicular lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, relapsed and refractory mantle cell lymphoma. It is formulated as a capsule and is administered through oral route. It acts by targeting histone deacetylase (HDAC). It was also under development for the treatment of lung cancer, colon cancer, gastric cancer, metastatic colorectal cancer, pancreatic cancer, nasopharyngeal cancer, haematological malignancies such as follicular non-Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL) as second line of therapy, refractory and relapsed multiple myeloma as first and second line of therapy, refractory and relapsed acute myeloid leukemia, acute lymphoblastic leukemia, high or intermediary-2 risk myelodysplastic syndrome and sarcomas as second line of therapy, fallopian tube cancer, peritoneal cancer, brain tumor and neuroblastoma. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Diffuse Large B-cell Lymphoma.

B-Cell Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different B-Cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in B-Cell Lymphoma

There are approx. 160+ key companies which are developing the therapies for B-Cell Lymphoma. The companies which have their B-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase III include, ZAI Lab.

Phases

This report covers around 170+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

B-Cell Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses B-Cell Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging B-Cell Lymphoma drugs.

B-Cell Lymphoma Report Insights

• B-Cell Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

B-Cell Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing B-Cell Lymphoma drugs?
• How many B-Cell Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of B-Cell Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the B-Cell Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for B-Cell Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Oncternal Therapeutics, Inc.
• ZAI Lab
• Pfizer
• Xynomic Pharmaceuticals
• Syst ImmuneInc.
• Autolus Limited
• Vincerx Pharma
• Ubix Therapeutics
• Biomea Fusion Inc.
• Shanghai Hengrui Pharmaceutical
• BeiGene
• Hanmi Pharmaceutical
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Merck Sharp & Dohme LLC
• Sanofi
• Inno CarePharma
• Allogene Therapeutics
• Cellular Biomedicine Group Ltd.
• Genentech
• Philogen
• Aleta Biotherapeutics
• Incyte Corporation
• Fundamenta Therapeutics, Ltd.
• Juventas Cell Therapy
• Shanghai Hengrui Pharmaceutical Co., Ltd.
• Guangzhou Lupeng Pharmaceutical Company LTD.
• TG Therapeutics Inc.
• Roche
• 2seventy bio
• AstraZeneca
• Nektar Therapeutics
• ADC Therapeutics
• Genor Biopharma
• Pacylex Pharmaceuticals
• Antengene Corporation
• Zhejiang DTRM Biopharma
• Shanghai Cell Therapy Group Co., Ltd.
• Nanjing Legend Biotech Co.

Key Products

• Zilovertamab
• Odronextamab
• PF-07901801
• Abexinostat
• GNC-038
• AUTO3
• VIP 924
• UBX-303-1
• BMF-219
• SHR-A1912
• Ociperlimab
• Poseltinib
• TQ-B3525
• DPX-Survivac
• THOR-707
• Orelabrutinib
• ALLO 501A
• Prizloncabtagene autoleucel
• Mosunetuzumab
• Bifikafusp alfa
• ALETA 001
• Parsaclisib
• CNCT-19
• SHR-A1912
• LP-168
• TG-1801
• Zanubrutinib
• BGB-11417
• BGB 16673
• ME-401
• BGB-10188
• Tafasitamab
• RG 6026
• ALLO-647
• bbT369
• Capivasertib
• NKTR-255
• Loncastuximab tesirine
• GB-241
• MK-2140
• PCLX-001
• ATG-008
• CC-122
• BZ019
• LCAR-AIO

This product will be delivered within 1-3 business days.